FDA Approved First siRNA Based New Class of Drug for a Rare Genetic Disease
FDA Approved First siRNA Based New Class of Drug for a Rare Genetic Disease By: Alnylam News Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the United States Food and Drug Administration (FDA) approved ONPATTRO™ (patisiran) lipid complex injection, a first-of-its-kind RNA interference (RNAi) therapeutic, for the treatment [..]